CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 3,388 enrolled
Drug / intervention
ProQuad®biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00560755
NCT00560755Phase 3Completed
CompareCT.gov

An Open-label, Multi-centre Study of the Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) Manufactured With Recombinant Human Albumin (rHA) When Administered to Children in Their Second Year of Life

Merck Sharp & Dohme LLC·interventional·Posted Nov 20, 2007·Updated Oct 17, 2017

In Brief

A Phase 3 clinical trial evaluating ProQuad® for Measles and 3 related conditions. Completed, enrolled 3,388 participants.

Detailed Summary

Primary objective: To describe the safety profile of a second dose of ProQuad® manufactured with recombinant human albumin (rHA) when administered to children in their second year of life. Secondary objectives: To describe the safety profile of a first dose of ProQuad® manufactured with rHA when administered to children in their second year of life.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMeasles, Mumps, Rubella, Varicella
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 20, 2007
Enrollment StartOct 24, 2007
Primary CompletionNov 24, 2008
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 18.6 years ago

Interventions

ProQuad®biological

ProQuad® manufactured with recombinant human albumin (rHA) is an investigational combined attenuated live virus vaccine for vaccination against measles, mumps, rubella and varicella viruses.